EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 121 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... March 9, 2021 Study Suggests a Link between Stress and Cancer Coming Back January 14, 2021 Elucidating a Risk of Developing Second Primary Malignancy During and After... August 12, 2021 ESMO Congress 2024 Barcelona, Spain, 13-17 September September 3, 2024 Load more HOT NEWS FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... Meet the teams tackling 5 challenges in children’s and young people’s... In memory of Dame Deborah James
